First Phase II clinical trial of AL001 for patients with mild to moderate Alzheimer's disease
Latest Information Update: 23 May 2025
At a glance
- Drugs Lithium cocrystal Alzamend Neuro (Primary)
- Indications Alzheimer's disease; Bipolar disorders; Major depressive disorder; Post-traumatic stress disorders
- Focus Registrational; Therapeutic Use
Most Recent Events
- 19 May 2025 According to an Alzamend Neuro media release, Status changed from not yet recruiting to completed.
- 19 May 2025 According to an Alzamend Neuro media release, results from this study of AL001 in Alzheimer's patients and healthy subjects identified a maximum tolerated dose (MTD), as assessed by an independent safety review committee.
- 13 May 2025 According to an Alzamend Neuro media release, topline data from this trial expected by year end.